Alaunos Therapeutics (TCRT) Change in Accured Expenses (2016 - 2025)
Historic Change in Accured Expenses for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to -$188000.0.
- Alaunos Therapeutics' Change in Accured Expenses fell 804.6% to -$188000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$290000.0, marking a year-over-year increase of 8927.12%. This contributed to the annual value of -$1.2 million for FY2024, which is 7081.98% up from last year.
- As of Q3 2025, Alaunos Therapeutics' Change in Accured Expenses stood at -$188000.0, which was down 804.6% from $35000.0 recorded in Q2 2025.
- Alaunos Therapeutics' 5-year Change in Accured Expenses high stood at $1.9 million for Q3 2022, and its period low was -$7.3 million during Q4 2021.
- In the last 5 years, Alaunos Therapeutics' Change in Accured Expenses had a median value of -$192000.0 in 2024 and averaged -$864789.5.
- Examining YoY changes over the last 5 years, Alaunos Therapeutics' Change in Accured Expenses showed a top increase of 20964.57% in 2021 and a maximum decrease of 60851.8% in 2021.
- Alaunos Therapeutics' Change in Accured Expenses (Quarter) stood at -$7.3 million in 2021, then surged by 70.13% to -$2.2 million in 2022, then increased by 21.07% to -$1.7 million in 2023, then skyrocketed by 88.91% to -$192000.0 in 2024, then increased by 2.08% to -$188000.0 in 2025.
- Its Change in Accured Expenses was -$188000.0 in Q3 2025, compared to $35000.0 in Q2 2025 and $55000.0 in Q1 2025.